{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:37:05Z","timestamp":1777289825317,"version":"3.51.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-026-00744-7","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:34:58Z","timestamp":1772350498000},"page":"269-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Management of Eosinophilic Esophagitis in Pediatrics"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-2462","authenticated-orcid":false,"given":"Julia","family":"Sessions","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-8171","authenticated-orcid":false,"given":"Calies","family":"Menard-Katcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-8587","authenticated-orcid":false,"given":"Nathalie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","volume":"120","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, et al. ACG clinical guideline: diagnosis and management of eosinophilic esophagitis. Am J Gastroenterol. 2025;120:31\u201359. https:\/\/doi.org\/10.14309\/ajg.0000000000003194.","journal-title":"Am J Gastroenterol"},{"key":"744_CR2","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1016\/j.cgh.2023.06.005","volume":"21","author":"JW Hahn","year":"2023","unstructured":"Hahn JW, Lee K, Shin JI, Cho SH, Turner S, Shin JU, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976-2022: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21:3270-84.e3277. https:\/\/doi.org\/10.1016\/j.cgh.2023.06.005.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/apt.15231","volume":"49","author":"P Navarro","year":"2019","unstructured":"Navarro P, Arias \u00c1, Arias-Gonz\u00e1lez L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019;49:1116\u201325. https:\/\/doi.org\/10.1111\/apt.15231.","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ajg.2014.316","volume":"110","author":"ET Jensen","year":"2015","unstructured":"Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110:626\u201332. https:\/\/doi.org\/10.1038\/ajg.2014.316.","journal-title":"Am J Gastroenterol"},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cgh.2017.06.036","volume":"16","author":"V Mukkada","year":"2018","unstructured":"Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16:495-503.e498. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.036.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s10620-020-06438-5","volume":"66","author":"JW Chang","year":"2021","unstructured":"Chang JW, Rubenstein JH, Mellinger JL, Kodroff E, Strobel MJ, Scott M, et al. Motivations, barriers, and outcomes of patient-reported shared decision making in eosinophilic esophagitis. Dig Dis Sci. 2021;66:1808\u201317. https:\/\/doi.org\/10.1007\/s10620-020-06438-5.","journal-title":"Dig Dis Sci"},{"key":"744_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","volume":"20","author":"I Hirano","year":"2022","unstructured":"Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20:525-34.e510. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2205982.","journal-title":"N Engl J Med"},{"key":"744_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","volume":"133","author":"GT Furuta","year":"2007","unstructured":"Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342\u201363. https:\/\/doi.org\/10.1053\/j.gastro.2007.08.017.","journal-title":"Gastroenterology"},{"issue":"1","key":"744_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","volume":"128","author":"CA Liacouras","year":"2011","unstructured":"Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3-20.e26. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.040.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","volume":"14","author":"AJ Lucendo","year":"2016","unstructured":"Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13-22.e11. https:\/\/doi.org\/10.1016\/j.cgh.2015.07.041.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","volume":"155","author":"ES Dellon","year":"2018","unstructured":"Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022-33.e1010. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.009.","journal-title":"Gastroenterology"},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/jaa.S274524","volume":"15","author":"JP Franciosi","year":"2022","unstructured":"Franciosi JP, Mougey EB, Dellon ES, Gutierrez-Junquera C, Fernandez-Fernandez S, Venkatesh RD, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281\u2013302. https:\/\/doi.org\/10.2147\/jaa.S274524.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"744_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1046\/j.1365-2036.2000.014s1074.x","volume":"14","author":"N Yoshida","year":"2000","unstructured":"Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors: inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(1):74\u201381. https:\/\/doi.org\/10.1046\/j.1365-2036.2000.014s1074.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1053\/j.gastro.2021.02.016","volume":"160","author":"E Odiase","year":"2021","unstructured":"Odiase E, Zhang X, Chang Y, Nelson M, Balaji U, Gu J, et al. In esophageal squamous cells from eosinophilic esophagitis patients, Th2 cytokines increase eotaxin-3 secretion through effects on intracellular calcium and a non-gastric proton pump. Gastroenterology. 2021;160:2072-88.e2076. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.016.","journal-title":"Gastroenterology"},{"key":"744_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050037","volume":"7","author":"X Zhang","year":"2012","unstructured":"Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS ONE. 2012;7:e50037. https:\/\/doi.org\/10.1371\/journal.pone.0050037.","journal-title":"PLoS ONE"},{"key":"744_CR17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jaci.2020.09.039","volume":"147","author":"M Rochman","year":"2021","unstructured":"Rochman M, Xie YM, Mack L, Caldwell JM, Klingler AM, Osswald GA, et al. Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors. J Allergy Clin Immunol. 2021;147:1924\u201335. https:\/\/doi.org\/10.1016\/j.jaci.2020.09.039.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MPG.0b013e31819c4b3e","volume":"49","author":"WN Sayej","year":"2009","unstructured":"Sayej WN, Patel R, Baker RD, Tron E, Baker SS. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;49:393\u20139. https:\/\/doi.org\/10.1097\/MPG.0b013e31819c4b3e.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpeds.2008.07.042","volume":"154","author":"JE Dranove","year":"2009","unstructured":"Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr. 2009;154:96\u2013100. https:\/\/doi.org\/10.1016\/j.jpeds.2008.07.042.","journal-title":"J Pediatr"},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MPG.0b013e3182716b7a","volume":"56","author":"S Schroeder","year":"2013","unstructured":"Schroeder S, Capocelli KE, Masterson JC, Harris R, Protheroe C, Lee JJ, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2013;56:166\u201372. https:\/\/doi.org\/10.1097\/MPG.0b013e3182716b7a.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jpedsurg.2012.11.006","volume":"48","author":"F Rea","year":"2013","unstructured":"Rea F, Caldaro T, Tambucci R, Romeo EF, Caloisi C, Torroni F, et al. Eosinophilic esophagitis: is it also a surgical disease? J Pediatr Surg. 2013;48:304\u20138. https:\/\/doi.org\/10.1016\/j.jpedsurg.2012.11.006.","journal-title":"J Pediatr Surg"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/mpg.0000000000001019","volume":"62","author":"C Guti\u00e9rrez-Junquera","year":"2016","unstructured":"Guti\u00e9rrez-Junquera C, Fern\u00e1ndez-Fern\u00e1ndez S, Cilleruelo ML, Rayo A, Echeverr\u00eda L, Quevedo S, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62:704\u201310. https:\/\/doi.org\/10.1097\/mpg.0000000000001019.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.18176\/jiaci.0230","volume":"28","author":"E G\u00f3mez Torrijos","year":"2018","unstructured":"G\u00f3mez Torrijos E, Donado Palencia P, Sanchez Miranda MP, Moreno Lozano L, Extremera Ortega AM, Borja Segade JM, et al. Eosinophilic esophagitis: treatment with different doses of omeprazole in children under 16 years. J Investig Allergol Clin Immunol. 2018;28:191\u20132. https:\/\/doi.org\/10.18176\/jiaci.0230.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"744_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doy029","author":"BR Harris","year":"2018","unstructured":"Harris BR, Hon E, Gupta SK. Implementation of guidelines in eosinophilic esophagitis at an academic pediatric practice. Dis Esophagus. 2018. https:\/\/doi.org\/10.1093\/dote\/doy029.","journal-title":"Dis Esophagus"},{"key":"744_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jped.2019.05.005","volume":"96","author":"GG Vieira","year":"2020","unstructured":"Vieira GG, Ribeiro LBM, Truppel SK, Ros\u00e1rio Filho NA, Vieira MC. Endoscopic and histological characteristics in patients with eosinophilic esophagitis responsive and non-responsive to proton pump inhibitors. J Pediatr Rio J. 2020;96:638\u201343. https:\/\/doi.org\/10.1016\/j.jped.2019.05.005.","journal-title":"J Pediatr Rio J"},{"key":"744_CR26","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/apa.15746","volume":"110","author":"I Rosen","year":"2021","unstructured":"Rosen I, Mahamed A, Garah J, Magen-Rimon R, Shaoul R. The management and course of eosinophilic oesophagitis in Israeli children. Acta Paediatr. 2021;110:1653\u20137. https:\/\/doi.org\/10.1111\/apa.15746.","journal-title":"Acta Paediatr"},{"key":"744_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/mpg.0000000000003660","volume":"76","author":"C Guti\u00e9rrez-Junquera","year":"2023","unstructured":"Guti\u00e9rrez-Junquera C, Fern\u00e1ndez-Fern\u00e1ndez S, Dom\u00ednguez-Ortega G, Vila Miravet V, Garc\u00eda-Puig R, La Orden-Izquierdo E, et al. Proton pump inhibitor therapy in pediatric eosinophilic esophagitis: predictive factors and long-term step-down efficacy. J Pediatr Gastroenterol Nutr. 2023;76:191\u20138. https:\/\/doi.org\/10.1097\/mpg.0000000000003660.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR28","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.cgh.2025.01.016","volume":"23","author":"AJ Lucendo","year":"2025","unstructured":"Lucendo AJ, Guti\u00e9rrez-Ram\u00edrez L, Tejera-Mu\u00f1oz A, Molina-Infante J, Arias \u00c1. Proton pump inhibitors for inducing and maintaining remission in eosinophilic esophagitis: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23:2115-27.e2121. https:\/\/doi.org\/10.1016\/j.cgh.2025.01.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR29","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.cgh.2020.08.020","volume":"19","author":"EB Mougey","year":"2021","unstructured":"Mougey EB, Nguyen V, Guti\u00e9rrez-Junquera C, Fern\u00e1ndez-Fern\u00e1ndez S, Cilleruelo ML, Rayo A, et al. STAT6 variants associate with relapse of eosinophilic esophagitis in patients receiving long-term proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2021;19:2046-53.e2042. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.020.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/mpg.0000000000002480","volume":"69","author":"EB Mougey","year":"2019","unstructured":"Mougey EB, Williams A, Coyne AJK, Guti\u00e9rrez-Junquera C, Fern\u00e1ndez-Fern\u00e1ndez S, Cilleruelo ML, et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;69:581\u20137. https:\/\/doi.org\/10.1097\/mpg.0000000000002480.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073685","author":"P Soria-Chacartegui","year":"2024","unstructured":"Soria-Chacartegui P, Navares-G\u00f3mez M, Molina-Jim\u00e9nez F, Laserna-Mendieta EJ, Arias-Gonz\u00e1lez L, Majano P, et al. Impact of STAT6 variants on the response to proton pump inhibitors and comorbidities in patients with eosinophilic esophagitis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073685.","journal-title":"Int J Mol Sci"},{"key":"744_CR32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/gutjnl-2012-302250","volume":"62","author":"E Cheng","year":"2013","unstructured":"Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62:824\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2012-302250.","journal-title":"Gut"},{"key":"744_CR33","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1007\/s10620-020-06633-4","volume":"66","author":"R Alexander","year":"2021","unstructured":"Alexander R, Alexander JA, Akambase J, Harmsen WS, Geno D, Tholen C, et al. Proton pump inhibitor therapy in eosinophilic esophagitis: predictors of nonresponse. Dig Dis Sci. 2021;66:3096\u2013104. https:\/\/doi.org\/10.1007\/s10620-020-06633-4.","journal-title":"Dig Dis Sci"},{"key":"744_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/apt.15957","volume":"52","author":"EJ Laserna-Mendieta","year":"2020","unstructured":"Laserna-Mendieta EJ, Casabona S, Guagnozzi D, Savarino E, Perell\u00f3 A, Guardiola-Ar\u00e9valo A, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther. 2020;52:798\u2013807. https:\/\/doi.org\/10.1111\/apt.15957.","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR35","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1007\/s00431-024-05618-z","volume":"183","author":"P Navarro","year":"2024","unstructured":"Navarro P, Feo-Ortega S, Casabona-Franc\u00e9s S, Guti\u00e9rrez-Junquera C, Savarino EV, Amorena E, et al. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry. Eur J Pediatr. 2024;183:3567\u201378. https:\/\/doi.org\/10.1007\/s00431-024-05618-z.","journal-title":"Eur J Pediatr"},{"key":"744_CR36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.14309\/ajg.0000000000002712","volume":"119","author":"M Muftah","year":"2024","unstructured":"Muftah M, Goldin AH, Barshop K, Hsu Blatman K, Hamilton MJ, Lo WK, et al. Twice-daily proton pump inhibitor induces higher remission rate in eosinophilic esophagitis than once-daily regimen regardless of total daily dose. Am J Gastroenterol. 2024;119:991\u20135. https:\/\/doi.org\/10.14309\/ajg.0000000000002712.","journal-title":"Am J Gastroenterol"},{"key":"744_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ajg.2015.314","volume":"110","author":"J Molina-Infante","year":"2015","unstructured":"Molina-Infante J, Rodriguez-Sanchez J, Martinek J, van Rhijn BD, Krajciova J, Rivas MD, et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol. 2015;110:1567\u201375. https:\/\/doi.org\/10.1038\/ajg.2015.314.","journal-title":"Am J Gastroenterol"},{"key":"744_CR38","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1016\/j.jaip.2022.09.022","volume":"10","author":"LB Robinson","year":"2022","unstructured":"Robinson LB, Ruffner MA. Proton pump inhibitors in allergy: benefits and risks. J Allergy Clin Immunol Pract. 2022;10:3117\u201323. https:\/\/doi.org\/10.1016\/j.jaip.2022.09.022.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"744_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.20452\/pamw.15997","volume":"131","author":"C Castellana","year":"2021","unstructured":"Castellana C, Pecere S, Furnari M, Telese A, Matteo MV, Haidry R, et al. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021;131:541\u20139. https:\/\/doi.org\/10.20452\/pamw.15997.","journal-title":"Pol Arch Intern Med"},{"key":"744_CR40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706\u201315. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.031.","journal-title":"Gastroenterology"},{"key":"744_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/00005176-199807000-00016","volume":"27","author":"WA Faubion Jr","year":"1998","unstructured":"Faubion WA Jr, Perrault J, Burgart LJ, Zein NN, Clawson M, Freese DK. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr. 1998;27:90\u20133. https:\/\/doi.org\/10.1097\/00005176-199807000-00016.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00005176-199804000-00004","volume":"26","author":"CA Liacouras","year":"1998","unstructured":"Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr. 1998;26:380\u20135. https:\/\/doi.org\/10.1097\/00005176-199804000-00004.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR43","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","volume":"139","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010;139:1526-37.e1521. https:\/\/doi.org\/10.1053\/j.gastro.2010.07.048.","journal-title":"Gastroenterology"},{"key":"744_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","volume":"139","author":"R Dohil","year":"2010","unstructured":"Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010;139:418\u201329. https:\/\/doi.org\/10.1053\/j.gastro.2010.05.001.","journal-title":"Gastroenterology"},{"key":"744_CR45","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/j.1572-0241.2007.01379.x","volume":"102","author":"SS Aceves","year":"2007","unstructured":"Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol. 2007;102:2271\u20139. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01379.x.","journal-title":"Am J Gastroenterol"},{"key":"744_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","volume":"10","author":"JA Alexander","year":"2012","unstructured":"Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10:742-9.e741. https:\/\/doi.org\/10.1016\/j.cgh.2012.03.018.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR47","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","volume":"147","author":"BK Butz","year":"2014","unstructured":"Butz BK, Wen T, Gleich GJ, Furuta GT, Spergel J, King E, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147:324-33.e325. https:\/\/doi.org\/10.1053\/j.gastro.2014.04.019.","journal-title":"Gastroenterology"},{"key":"744_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","volume":"157","author":"ES Dellon","year":"2019","unstructured":"Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology. 2019;157:65-73.e65. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.014.","journal-title":"Gastroenterology"},{"key":"744_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jpn3.12273","volume":"79","author":"N Lendner","year":"2024","unstructured":"Lendner N, Minich NM, Malay S, Sferra TJ, Young DD. Comparison of budesonide vehicles in inducing histologic remission in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2024;79:92\u20139. https:\/\/doi.org\/10.1002\/jpn3.12273.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/mpg.0000000000003834","volume":"77","author":"EP Syverson","year":"2023","unstructured":"Syverson EP, Tobin M, Patton T, Franciosi JP, Gupta SK, Venkatesh RD. Variability in swallowed topical corticosteroid practice patterns for treatment of pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2023;77:256\u20139. https:\/\/doi.org\/10.1097\/mpg.0000000000003834.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR51","doi-asserted-by":"publisher","first-page":"CD004065","DOI":"10.1002\/14651858.CD004065.pub4","volume":"7","author":"JP Franciosi","year":"2023","unstructured":"Franciosi JP, Gordon M, Sinopoulou V, Dellon ES, Gupta SK, Reed CC, et al. Medical treatment of eosinophilic esophagitis. Cochrane Database Syst Rev. 2023;7:CD004065. https:\/\/doi.org\/10.1002\/14651858.CD004065.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"744_CR52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.20524\/aog.2023.0822","volume":"36","author":"L Numan","year":"2023","unstructured":"Numan L, Kalot MA, Brotherton T, Tarakji A, Hamdeh S. Comparison of viscous budesonide and fluticasone in the treatment of patients with eosinophilic esophagitis: a systematic review and meta-analysis. Ann Gastroenterol. 2023;36:511\u20136. https:\/\/doi.org\/10.20524\/aog.2023.0822.","journal-title":"Ann Gastroenterol"},{"key":"744_CR53","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.gie.2015.11.019","volume":"83","author":"S Eluri","year":"2016","unstructured":"Eluri S, Runge TM, Cotton CC, Burk CM, Wolf WA, Woosley JT, et al. The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis. Gastrointest Endosc. 2016;83:1142\u20138. https:\/\/doi.org\/10.1016\/j.gie.2015.11.019.","journal-title":"Gastrointest Endosc"},{"key":"744_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.gie.2022.05.013","volume":"96","author":"SS Aceves","year":"2022","unstructured":"Aceves SS, Alexander JA, Baron TH, Bredenoord AJ, Day L, Dellon ES, et al. Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference. Gastrointest Endosc. 2022;96:576-92. e571. https:\/\/doi.org\/10.1016\/j.gie.2022.05.013.","journal-title":"Gastrointest Endosc"},{"key":"744_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","volume":"157","author":"AJ Lucendo","year":"2019","unstructured":"Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157:74-86.e15. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.025.","journal-title":"Gastroenterology"},{"key":"744_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ueg2.12533","volume":"12","author":"EJ Laserna-Mendieta","year":"2024","unstructured":"Laserna-Mendieta EJ, Navarro P, Casabona-Franc\u00e9s S, Savarino EV, Amorena E, P\u00e9rez-Mart\u00ednez I, et al. Swallowed topical corticosteroids for eosinophilic esophagitis: utilization and real-world efficacy from the EoE CONNECT registry. United Eur Gastroenterol J. 2024;12:585\u201395. https:\/\/doi.org\/10.1002\/ueg2.12533.","journal-title":"United Eur Gastroenterol J"},{"key":"744_CR57","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/MPG.0000000000003948","volume":"77","author":"VA Mukkada","year":"2023","unstructured":"Mukkada VA, Gupta SK, Gold BD, Dellon ES, Collins MH, Katzka DA, et al. Pooled phase 2 and 3 efficacy and safety data on budesonide oral suspension in adolescents with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2023;77:760\u20138. https:\/\/doi.org\/10.1097\/MPG.0000000000003948.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.024","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Katzka DA, Mukkada VA, Collins MH, Falk GW, Richmond CA, et al. Long-term safety and efficacy of budesonide oral suspension for eosinophilic esophagitis: a 4-year, phase 3, open-label study. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.024.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR59","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrgastro.2017.56","volume":"14","author":"ES Dellon","year":"2017","unstructured":"Dellon ES. Management of refractory eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol. 2017;14:479\u201390. https:\/\/doi.org\/10.1038\/nrgastro.2017.56.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"744_CR60","doi-asserted-by":"publisher","DOI":"10.2196\/43008","volume":"7","author":"B Darcy","year":"2023","unstructured":"Darcy B, Rashford L, Shultz ST, Tsai NT, Huizenga D, Reed KB, et al. Gait device treatment using Telehealth for individuals with stroke during the COVID-19 pandemic: nonrandomized pilot feasibility study. JMIR Form Res. 2023;7:e43008. https:\/\/doi.org\/10.2196\/43008.","journal-title":"JMIR Form Res"},{"key":"744_CR61","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cgh.2022.02.013","volume":"20","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Lucendo AJ, Schlag C, Schoepfer AM, Falk GW, Eagle G, et al. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial. Clin Gastroenterol Hepatol. 2022;20:2485-94.e2415. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.013.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR62","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/apt.18443","volume":"61","author":"AJ Lucendo","year":"2025","unstructured":"Lucendo AJ, Nantes-Castillejo \u00d3, Straumann A, Biedermann L, Bredenoord AJ, Guagnozzi D, et al. Clinical trial: safety and efficacy of a novel oesophageal delivery system for topical corticosteroids versus placebo in the treatment of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2025;61:444\u201355. https:\/\/doi.org\/10.1111\/apt.18443.","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR63","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0016-5085(95)90637-1","volume":"109","author":"KJ Kelly","year":"1995","unstructured":"Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109:1503\u201312. https:\/\/doi.org\/10.1016\/0016-5085(95)90637-1.","journal-title":"Gastroenterology"},{"key":"744_CR64","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/apt.13953","volume":"45","author":"MJ Warners","year":"2017","unstructured":"Warners MJ, Vlieg-Boerstra BJ, Verheij J, van Rhijn BD, Van Ampting MT, Harthoorn LF, et al. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. Aliment Pharmacol Ther. 2017;45:777\u201387. https:\/\/doi.org\/10.1111\/apt.13953.","journal-title":"Aliment Pharmacol Ther"},{"key":"744_CR65","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.14309\/ajg.0000000000001949","volume":"117","author":"A Zalewski","year":"2022","unstructured":"Zalewski A, Doerfler B, Krause A, Hirano I, Gonsalves N. Long-term outcomes of the six-food elimination diet and food reintroduction in a large cohort of adults with eosinophilic esophagitis. Am J Gastroenterol. 2022;117:1963\u201370. https:\/\/doi.org\/10.14309\/ajg.0000000000001949.","journal-title":"Am J Gastroenterol"},{"key":"744_CR66","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cgh.2006.05.026","volume":"4","author":"AF Kagalwalla","year":"2006","unstructured":"Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006;4:1097\u2013102. https:\/\/doi.org\/10.1016\/j.cgh.2006.05.026.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/nu16142231","author":"A Arias","year":"2024","unstructured":"Arias A, Tejera-Munoz A, Gutierrez-Ramirez L, Molina-Infante J, Lucendo AJ, EUREOS Guidelines Committee. Efficacy of dietary therapy for eosinophilic esophagitis in children and adults: an updated systematic review and meta-analysis. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16142231.","journal-title":"Nutrients"},{"key":"744_CR68","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.cgh.2017.05.048","volume":"15","author":"AF Kagalwalla","year":"2017","unstructured":"Kagalwalla AF, Wechsler JB, Amsden K, Schwartz S, Makhija M, Olive A, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15:1698-707.e1697. https:\/\/doi.org\/10.1016\/j.cgh.2017.05.048.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.820192","volume":"9","author":"M Votto","year":"2021","unstructured":"Votto M, De Filippo M, Lenti MV, Rossi CM, Di Sabatino A, Marseglia GL, et al. Diet therapy in eosinophilic esophagitis: focus on a personalized approach. Front Pediatr. 2021;9:820192. https:\/\/doi.org\/10.3389\/fped.2021.820192.","journal-title":"Front Pediatr"},{"key":"744_CR70","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1053\/j.gastro.2014.02.006","volume":"146","author":"A Arias","year":"2014","unstructured":"Arias A, Gonz\u00e1lez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146:1639\u201348. https:\/\/doi.org\/10.1053\/j.gastro.2014.02.006.","journal-title":"Gastroenterology"},{"key":"744_CR71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/s2468-1253(23)00012-2","volume":"8","author":"KL Kliewer","year":"2023","unstructured":"Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, et al. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Lancet Gastroenterol Hepatol. 2023;8:408\u201321. https:\/\/doi.org\/10.1016\/s2468-1253(23)00012-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"744_CR72","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2024.08.023","volume":"155","author":"KL Kliewer","year":"2025","unstructured":"Kliewer KL, Abonia JP, Aceves SS, Atkins D, Bonis PA, Capocelli KE, et al. One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: a\u00a0multisite randomized trial. J Allergy Clin Immunol. 2025;155:520\u201332. https:\/\/doi.org\/10.1016\/j.jaci.2024.08.023.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR73","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jaci.2013.08.017","volume":"132","author":"J Leung","year":"2013","unstructured":"Leung J, Hundal NV, Katz AJ, Shreffler WG, Yuan Q, Butterworth CA, et al. Tolerance of baked milk in patients with cow\u2019s milk-mediated eosinophilic esophagitis. J Allergy Clin Immunol. 2013;132:1215-6.e1211. https:\/\/doi.org\/10.1016\/j.jaci.2013.08.017.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR74","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000217","volume":"6","author":"TM Brown","year":"2019","unstructured":"Brown TM, Leung J. Tolerance of baked cheese in cow\u2019s milk-mediated eosinophilic esophagitis. ACG Case Rep J. 2019;6:e00217. https:\/\/doi.org\/10.14309\/crj.0000000000000217.","journal-title":"ACG Case Rep J"},{"key":"744_CR75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.gie.2015.05.044","volume":"83","author":"JA Friedlander","year":"2016","unstructured":"Friedlander JA, DeBoer EM, Soden JS, Furuta GT, Menard-Katcher CD, Atkins D, et al. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. Gastrointest Endosc. 2016;83:299-306.e291. https:\/\/doi.org\/10.1016\/j.gie.2015.05.044.","journal-title":"Gastrointest Endosc"},{"key":"744_CR76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.cgh.2021.11.021","volume":"20","author":"N Nguyen","year":"2022","unstructured":"Nguyen N, Mark J, Furuta GT. Emerging role of transnasal endoscopy in children and adults. Clin Gastroenterol Hepatol. 2022;20:501\u20134. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR77","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001563","volume":"11","author":"S Eid","year":"2024","unstructured":"Eid S, Bauer M, Nguyen N. The role of transnasal endoscopy in diet management of eosinophilic esophagitis. ACG Case Rep J. 2024;11:e01563. https:\/\/doi.org\/10.14309\/crj.0000000000001563.","journal-title":"ACG Case Rep J"},{"key":"744_CR78","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.14309\/ajg.0000000000000371","volume":"114","author":"SJ Ackerman","year":"2019","unstructured":"Ackerman SJ, Kagalwalla AF, Hirano I, Gonsalves N, Katcher PM, Gupta S, et al. One-hour esophageal string test: a nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis. Am J Gastroenterol. 2019;114:1614\u201325. https:\/\/doi.org\/10.14309\/ajg.0000000000000371.","journal-title":"Am J Gastroenterol"},{"key":"744_CR79","doi-asserted-by":"publisher","first-page":"254","DOI":"10.14309\/ajg.0000000000003192","volume":"120","author":"SJ Ackerman","year":"2025","unstructured":"Ackerman SJ, Kagalwalla AF, Pan Z, Wechsler J, Keeley K, Gonsalves N, et al. The minimally invasive 1-hour esophageal string test monitors therapeutic changes in mucosal inflammation in eosinophilic esophagitis. Am J Gastroenterol. 2025;120:254\u20138. https:\/\/doi.org\/10.14309\/ajg.0000000000003192.","journal-title":"Am J Gastroenterol"},{"key":"744_CR80","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1136\/gutjnl-2012-303171","volume":"62","author":"GT Furuta","year":"2013","unstructured":"Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013;62:1395\u2013405. https:\/\/doi.org\/10.1136\/gutjnl-2012-303171.","journal-title":"Gut"},{"key":"744_CR81","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00455-016-9739-1","volume":"31","author":"W Asher Wolf","year":"2016","unstructured":"Asher Wolf W, Huang KZ, Durban R, Iqbal ZJ, Robey BS, Khalid FJ, et al. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia. 2016;31:765\u201370. https:\/\/doi.org\/10.1007\/s00455-016-9739-1.","journal-title":"Dysphagia"},{"key":"744_CR82","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1007\/s10620-018-5045-0","volume":"63","author":"R Wang","year":"2018","unstructured":"Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Dig Dis Sci. 2018;63:1756\u201362. https:\/\/doi.org\/10.1007\/s10620-018-5045-0.","journal-title":"Dig Dis Sci"},{"key":"744_CR83","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000540228","volume":"9","author":"J Chahuan","year":"2024","unstructured":"Chahuan J, Lucendo AJ. Dietary treatment for children and adults with eosinophilic esophagitis: which patient and which doctor is it suitable for? Inflamm Intest Dis. 2024;9:184\u20138. https:\/\/doi.org\/10.1159\/000540228.","journal-title":"Inflamm Intest Dis"},{"key":"744_CR84","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2017.08.038","volume":"141","author":"J Molina-Infante","year":"2018","unstructured":"Molina-Infante J, Arias \u00c1, Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141:1365\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2017.08.038.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR85","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.cgh.2018.04.013","volume":"16","author":"T Zhan","year":"2018","unstructured":"Zhan T, Ali A, Choi JG, Lee M, Leung J, Dellon ES, et al. Model to determine the optimal dietary elimination strategy for\u00a0treatment of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2018;16:1730-7.e1732. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.013.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR86","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"key":"744_CR87","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666x.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425\u201337. https:\/\/doi.org\/10.1080\/1744666x.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"key":"744_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50:5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"key":"744_CR89","unstructured":"Regeneron Pharmaceuticals. Dupixent: Highlights of Prescribing Information. 2025. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 10 Sept 2025."},{"key":"744_CR90","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","volume":"8","author":"ME Rothenberg","year":"2023","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8:990\u20131004. https:\/\/doi.org\/10.1016\/S2468-1253(23)00204-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"744_CR91","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","volume":"390","author":"M Chehade","year":"2024","unstructured":"Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024;390:2239\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2312282.","journal-title":"N Engl J Med"},{"key":"744_CR92","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/gutjnl-2023-330220","volume":"73","author":"AJ Bredenoord","year":"2024","unstructured":"Bredenoord AJ, Dellon ES, Hirano I, Lucendo AJ, Schlag C, Sun X, et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 2024;73:398\u2013406. https:\/\/doi.org\/10.1136\/gutjnl-2023-330220.","journal-title":"Gut"},{"key":"744_CR93","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.000000000000359.9","author":"M Chehade","year":"2025","unstructured":"Chehade M, Oliva S, Ashok D, Liu R, Maloney J, Abdulai RM, et al. Dupilumab efficacy in children with eosinophilic esophagitis with prior swallowed topical corticosteroid use: a subgroup analysis. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.000000000000359.9.","journal-title":"Am J Gastroenterol"},{"key":"744_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-024-05313-w","volume":"25","author":"M Hasosah","year":"2025","unstructured":"Hasosah M, Sukkar G, AlSahafi A, Zaidan A, Ghous N, Alshahrani A, et al. Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study. BMC Pediatr. 2025;25:100. https:\/\/doi.org\/10.1186\/s12887-024-05313-w.","journal-title":"BMC Pediatr"},{"key":"744_CR95","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2023.08.015","volume":"22","author":"CJ Lee","year":"2024","unstructured":"Lee CJ, Dellon ES. Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2024;22:252\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2023.08.015.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR96","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.anai.2022.12.014","volume":"130","author":"SS Aceves","year":"2023","unstructured":"Aceves SS, Dellon ES, Greenhawt M, Hirano I, Liacouras CA, Spergel JM. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: a yardstick. Ann Allergy Asthma Immunol. 2023;130:371\u20138. https:\/\/doi.org\/10.1016\/j.anai.2022.12.014.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"744_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox042","volume":"30","author":"TM Runge","year":"2017","unstructured":"Runge TM, Eluri S, Woosley JT, Shaheen NJ, Dellon ES. Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis. Dis Esophagus. 2017;30:1\u20137. https:\/\/doi.org\/10.1093\/dote\/dox042.","journal-title":"Dis Esophagus"},{"key":"744_CR98","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/ajg.2009.657","volume":"105","author":"AM Schoepfer","year":"2010","unstructured":"Schoepfer AM, Gonsalves N, Bussmann C, Conus S, Simon HU, Straumann A, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol. 2010;105:1062\u201370. https:\/\/doi.org\/10.1038\/ajg.2009.657.","journal-title":"Am J Gastroenterol"},{"key":"744_CR99","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/MPG.0000000000001336","volume":"64","author":"C Menard-Katcher","year":"2017","unstructured":"Menard-Katcher C, Furuta GT, Kramer RE. Dilation of pediatric eosinophilic esophagitis: adverse events and short-term outcomes. J Pediatr Gastroenterol Nutr. 2017;64:701\u20136. https:\/\/doi.org\/10.1097\/MPG.0000000000001336.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR100","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/mpg.0000000000002823","volume":"71","author":"N Nguyen","year":"2020","unstructured":"Nguyen N, Hayes K, Fenton L, Furuta GT, Menard-Katcher C. Case series: role of pill esophagram to identify pediatric patients with eosinophilic esophagitis amenable to therapeutic dilation. J Pediatr Gastroenterol Nutr. 2020;71:530\u20132. https:\/\/doi.org\/10.1097\/mpg.0000000000002823.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR101","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","volume":"72","author":"ES Dellon","year":"2023","unstructured":"Dellon ES, Peterson KA, Mitlyng BL, Iuga A, Bookhout CE, Cortright LM, et al. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Gut. 2023;72:1828\u201337. https:\/\/doi.org\/10.1136\/gutjnl-2023-330337.","journal-title":"Gut"},{"key":"744_CR102","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","volume":"118","author":"ML Stein","year":"2006","unstructured":"Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118:1312\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2006.09.007.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR103","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59:21\u201330. https:\/\/doi.org\/10.1136\/gut.2009.178558.","journal-title":"Gut"},{"key":"744_CR104","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","volume":"141","author":"AH Assa\u2019ad","year":"2011","unstructured":"Assa\u2019ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141:1593\u2013604. https:\/\/doi.org\/10.1053\/j.gastro.2011.07.044.","journal-title":"Gastroenterology"},{"key":"744_CR105","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs 3rdG, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456-63.e451-53. https:\/\/doi.org\/10.1016\/j.jaci.2011.11.044.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR106","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","volume":"66","author":"JE Markowitz","year":"2018","unstructured":"Markowitz JE, Jobe L, Miller M, Frost C, Laney Z, Eke R. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr. 2018;66:893\u20137. https:\/\/doi.org\/10.1097\/MPG.0000000000001840.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"744_CR107","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","volume":"390","author":"ME Rothenberg","year":"2024","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, et al. Eosinophil depletion with benralizumab for eosinophilic esophagitis. N Engl J Med. 2024;390:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2313318.","journal-title":"N Engl J Med"},{"key":"744_CR108","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","volume":"147","author":"F Clayton","year":"2014","unstructured":"Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147:602\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2014.05.036.","journal-title":"Gastroenterology"},{"key":"744_CR109","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","volume":"117","author":"E Dellon","year":"2022","unstructured":"Dellon E, Chehade M, Genta RM, Leiman DA, Peterson KA, Spergel J, et al. S446 results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE. Am J G Gastroenterol. 2022;117:e316\u20137. https:\/\/doi.org\/10.14309\/01.ajg.0000858424.48968.ad.","journal-title":"Am J G Gastroenterol."},{"key":"744_CR110","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","volume":"156","author":"I Hirano","year":"2019","unstructured":"Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. RPC4046, a monoclonal antibody against IL13, reduces\u00a0histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156:592-03.e510. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.051.","journal-title":"Gastroenterology"},{"key":"744_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107708","volume":"147","author":"CM Charriez","year":"2024","unstructured":"Charriez CM, Zhang S, de Oliveira C, Patel V, Oh YS, Hirano I, et al. Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis. Contemp Clin Trials. 2024;147:107708. https:\/\/doi.org\/10.1016\/j.cct.2024.107708.","journal-title":"Contemp Clin Trials"},{"key":"744_CR112","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500095","volume":"4","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Charriez CM, Zhang S, Falk GW, Oliva S, Ma C, et al. Cendakimab in adults and adolescents with eosinophilic esophagitis. NEJM Evid. 2025;4:EVIDoa2500095. https:\/\/doi.org\/10.1056\/EVIDoa2500095.","journal-title":"NEJM Evid"},{"issue":"11","key":"744_CR113","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1111\/all.16682","volume":"80","author":"A Dsilva","year":"2025","unstructured":"Dsilva A, Wagner A, Itan M, Rhone N, Avlas S, Gordon Y, et al. Distinct roles for thymic stromal lymphopoietin (TSLP) and IL-33 in experimental eosinophilic esophagitis. Allergy. 2025;80(11):3095\u2013107. https:\/\/doi.org\/10.1111\/all.16682.","journal-title":"Allergy"},{"key":"744_CR114","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Tezepelumab: first approval. Drugs. 2022;82:461\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01679-2.","journal-title":"Drugs"},{"key":"744_CR115","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaci.2018.05.018","volume":"142","author":"JB Wechsler","year":"2018","unstructured":"Wechsler JB, Hirano I. Biological therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol. 2018;142:24-31.e22. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.018.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR116","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/cea.13550","volume":"50","author":"Y Riffo-Vasquez","year":"2020","unstructured":"Riffo-Vasquez Y, Kanabar V, Keir SD, E-Lacerda RR, Man F, Jackson DJ, et al. Modulation of allergic inflammation in the lung by a peptide derived from Mycobacteria tuberculosis chaperonin 60.1. Clin Exp Allergy. 2020;50:508\u201319. https:\/\/doi.org\/10.1111\/cea.13550.","journal-title":"Clin Exp Allergy"},{"key":"744_CR117","doi-asserted-by":"publisher","first-page":"L803","DOI":"10.1152\/ajplung.00155.2021","volume":"321","author":"F Man","year":"2021","unstructured":"Man F, Nadkarni S, Kanaba V, E-Lacerda RR, Gomes Ferreira S, Federici Canova D, et al. A peptide derived from chaperonin 60.1, IRL201104, inhibits LPS-induced acute lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2021;321:L803\u201313. https:\/\/doi.org\/10.1152\/ajplung.00155.2021.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR118","unstructured":"Revolo Biotherapeutics. Pipeline \u20181104\u2019, 2024. Available from: https:\/\/revolobio.com\/product-development-landscape-1104\/. Accessed 7 Aug 2025."},{"key":"744_CR119","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/s2468-1253(25)00062-7","volume":"10","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, et al. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2025;10:622\u201333. https:\/\/doi.org\/10.1016\/s2468-1253(25)00062-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"744_CR120","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","volume":"9","author":"AP Vicari","year":"2017","unstructured":"Vicari AP, Schoepfer AM, Meresse B, Goffin L, L\u00e9ger O, Josserand S, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs. 2017;9:927\u201344. https:\/\/doi.org\/10.1080\/19420862.2017.1332553.","journal-title":"MAbs"},{"key":"744_CR121","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1053\/j.gastro.2024.02.011","volume":"166","author":"M Nelson","year":"2024","unstructured":"Nelson M, Zhang X, Podgaetz E, Melmed A, Spechler SJ, Souza RF. In human esophageal epithelial and muscle cells treated with Th2 cytokines, upadacitinib decreases eotaxin-3 secretion and muscle tension. Gastroenterology. 2024;166:1166-9.e1163. https:\/\/doi.org\/10.1053\/j.gastro.2024.02.011.","journal-title":"Gastroenterology"},{"key":"744_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157376","volume":"11","author":"E Cheng","year":"2016","unstructured":"Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, et al. JAK-STAT6 pathway inhibitors block eotaxin-3 secretion by epithelial cells and fibroblasts from esophageal eosinophilia patients: promising agents to improve inflammation and prevent fibrosis in EoE. PLoS ONE. 2016;11:e0157376. https:\/\/doi.org\/10.1371\/journal.pone.0157376.","journal-title":"PLoS ONE"},{"key":"744_CR123","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaci.2008.06.012","volume":"122","author":"A Straumann","year":"2008","unstructured":"Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol. 2008;122:425\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2008.06.012.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR124","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.cgh.2018.06.022","volume":"16","author":"TH Taft","year":"2018","unstructured":"Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and\u00a0Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2018;16:1840\u20131. https:\/\/doi.org\/10.1016\/j.cgh.2018.06.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"744_CR125","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41395-018-0145-1","volume":"113","author":"QM Nhu","year":"2018","unstructured":"Nhu QM, Chiao H, Moawad FJ, Bao F, Konijeti GG. The anti-\u03b14\u03b27 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates eosinophilic esophagitis: a novel clinical observation. Am J Gastroenterol. 2018;113:1261\u20133. https:\/\/doi.org\/10.1038\/s41395-018-0145-1.","journal-title":"Am J Gastroenterol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00744-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00744-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00744-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:48:52Z","timestamp":1777286932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00744-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00744-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julia Sessions has no conflicts of interests that are directly relevant to the content of this article. Maureen Bauer is a consultant for Regeneron and Sanofi and receives royalties from Dynamed. Calies Menard-Katcher is an ad hoc consultant for Regeneron and Sanofi. Nathalie Nguyen is a consultant for Regeneron, Sanofi, and EvoEndo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JS and NN outlined the manuscript, critically appraised the literature, and drafted the manuscript. MB and CMK critically reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}